5:00 – 6:00 pm Thursday, October 28

Lighting the Way in COG with MATCH: Targeted Therapies in Pediatric CNS Tumors (C211)

coglogoPediatric MATCH (Molecular Analysis for Therapy Choice) is a joint effort between the National Cancer Institute (NCI) and Children’s Oncology Group (COG) matching targeted therapies to specific tumor genomic sequencing in patients with relapsed or refractory solid tumors, non-Hodgkin lymphomas, brain tumors, and histiocytic disorders.

11:30 am – 12:30 pm Friday, October 29

Post-Transplant Lymphoproliferative Disorder: Managing the Complexities of the Pediatric Solid Organ Transplant Patient (212)

Posttransplant lymphoproliferative disorders (PTLDs) are recognized as one of the most devastating complications following solid organ transplantation. PTLD encompasses a wide range of clinical conditions—from benign lymphoproliferation to widespread malignancies with aggressive behavior. The development of PTLDs is driven by Epstein-Barr virus in the vast majority of pediatric PTLD cases.

3:30 – 4:30 pm Thursday, October 28

Administration and Management of Anti-GD2 Immunotherapy for High Risk Neuroblastoma in the Outpatient Setting (200)

Neuroblastoma, the most common extracranial solid tumor in children, develops from neural crest cells that, typically, differentiate to form the sympathetic nervous system. Most neuroblastoma cases present as high-risk neuroblastoma, which has long been associated with high relapse rates and poor survival.

Subscribe to this RSS feed